ClinicalTrials.gov
public full text
Public Domain
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Related documents
- DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER#454023
- Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer#859569
- Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer#123442
- Real-world activity of trastuzumab deruxtecan in heavily pretreated HER2-expressing ovarian cancer: focusing on HER2-low responses and CCNE1 amplification#410918
- Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial#836836
Record · ID 28306 · SHA-256 17c3746fc8cd5ac2
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive